

Publications of the Week

TRIM24 Controls Induction of Latent HIV-1 by Stimulating Transcriptional Elongation

First Author: Riley Horvath | Senior Author: Ivan Sadowski (pictured)
Communications Biology | UBC



Binding of USF1/2 and TFII-I at conserved sites flanking the HIV-1 long terminal repeat (LTR) enhancer is essential for reactivation from latency in T cells, with TFII-I knockdown rendering the provirus insensitive to T cell signalling. The authors identified an interaction of TFII-I with the tripartite motif protein TRIM24, and these factors were found to be constitutively associated with the HIV-1 LTR. [Abstract](#)

Recent Advancements in Immunotherapy of Melanoma Using Nanotechnology-Based Strategies

First Author: Amrithossein Bahreyni | Senior Author: Honglin Luo (pictured)
Biomedicine & Pharmacotherapy | Centre for Heart Lung Innovation and UBC



Melanoma is a malignant tumour that accounts for the deadliest form of skin cancers. Several studies have shown that proper application of nanomaterials can revolutionize the outcome of immunotherapy in diverse melanoma models. This review summarizes the recent advancement in the integration of nanotechnology and cancer immunotherapy in melanoma treatment. [Abstract](#)

[View All Publications](#)

Awards

UBC Biologist Wins Prize for Research on 'Dazzling' Explosions of Evolution


UBC Science



UBC evolutionary biologist Dr. Dolph Schluter (pictured) has been awarded the Crafoord Prize in Biosciences by the Royal Swedish Academy of Sciences (RSAS) and the Crafoord Foundation for his research into the role of natural selection in adaptive radiation and the origin of species. The Crafoord Prize, which includes 6,000,000 Swedish krona (\$780,000 CAD) to fund further research by the winner, is awarded by the RSAS in disciplines not considered for Nobel Prizes. [Read More](#)

Dr. Tim Kieffer Receives Funding Through the JDRF-CIHR Partnership to Defeat Diabetes

Life Sciences Institute (LSI)



The LSI's Dr. Tim Kieffer (pictured) was recently awarded funding for a project, "Designing stem cell-derived islets for diabetes therapy," through the JDRF-CIHR Partnership to Defeat Diabetes, a joint investment by the Canadian Institutes of Health Research (CIHR), Diabetes Canada, and the Juvenile Diabetes Research Foundation (JDRF) Canada. [Read More](#)

[View All Featured Awards](#) | [View Monthly Award Summaries](#)

Local News

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals



Jazz Pharmaceuticals and Zymeworks have announced tolerability and efficacy results, including the first overall survival data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma. [Read More](#)

Traffic Pollution Impairs Brain Function

UBC Faculty of Medicine



A new study by researchers at UBC and the University of Victoria has shown that common levels of traffic pollution can impair human brain function in only a matter of hours. "For many decades, scientists thought the brain may be protected from the harmful effects of air pollution," said senior study author Dr. Chris Carlsten (pictured), Professor and Head of Respiratory Medicine at UBC. "This study, which is the first of its kind in the world, provides fresh evidence supporting a connection between air pollution and cognition." [Read More](#)

Research by UBC Professor Lays Groundwork for Life-Saving Breast Cancer Treatment

UBC Faculty of Medicine



A drug originally designed to prevent osteoporosis is now expected to save and improve the lives of millions of people with breast cancer, thanks in part to decades of foundational research by Dr. Josef Penninger (pictured), a Professor in UBC's Faculty of Medicine and Director of the Life Sciences Institute. The drug, called Denosumab, was recently shown in a long-term Phase 3 clinical trial to improve survival among postmenopausal women with hormone receptor-positive early breast cancer receiving aromatase inhibitor treatment. [Read More](#)

[View All Articles](#) | [Submit an Article](#)

Upcoming Events in Vancouver

- February 7 10:00 AM **Academic-Industry Partnerships Roundtable**
Online
- February 24 4:00 PM **D.R.I.N.K.S. Vancouver**
Mahony and Sons
- March 3 1:00 PM **Three Minute Thesis: VCHRI and UBC Heat**
Vancouver Coastal Health Research Institute
- March 9 3:00 PM **Global Health Access & Equity Issues in LMICs and HICs: Compare & Contrast**
UBC
- March 16 7:00 PM **Spring Break Science Slam**
Fox Cabaret

[View All Events](#) | [Submit an Event](#)

STEMCELL Jobs in Vancouver

- Director, Quality Control, CMC Operations**
STEMCELL Technologies
- Manufacturing Technologist, Clean Room**
STEMCELL Technologies
- Customer Support Coordinator**
STEMCELL Technologies
- Senior Lab Manager**
STEMCELL Technologies
- Quality Engineer, Validation**
STEMCELL Technologies

[View 103 Other STEMCELL Jobs](#)

Other Science Jobs in Vancouver

- Computational Biologist, Ryan Morin Lab**
Canada's Michael Smith Genome Sciences Centre
- Scientific Writer**
AbCellera
- Research Technician**
UBC
- Research Associate II, Protein Engineering (Screening & Purification)**
Zymeworks
- Computational Biologist**
Imagia Canexia Health

[View 47 Other Science Jobs](#) | [Submit a Job](#)

Free Wallchart: Small Molecules in Cancer Research
STEMCELL TECHNOLOGIES
[REQUEST A COPY](#)

Submit your articles and events by reaching out to us at info@scienceinvancouver.com.

BROUGHT TO YOU BY



STEMCELL Technologies
Products | Services

STEMCELL Science News
Free Weekly Updates on Your Field

The Stem Cell Podcast
Interviews and Updates on Stem Cell Science